Search results for: “excel”

  • CPIC® guideline for statins and SLCO1B1, ABCG2, and CYP2C9

    Most recent guideline publication: The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022) Updates since publication: none Tables provided in the main manuscript of the guideline: Table 1. Assignment of predicted SLCO1B1, ABCG2, and CYP2C9 likely phenotype based on genotype Table 2. Dosing recommendations for statins…

  • CPIC® Guideline for G6PD

    Guideline overview presentation Most recent guideline publication: Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022) Tables  provided in the main manuscript of the guideline: Table 1. Assignment of predicted G6PD phenotype based on genotype Table 2. Drug-specific risk level and associated strength of recommendation for…

  • CPIC® Guideline for Aminoglycosides and MT-RNR1

    Most recent guideline publication: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021) Updates since publication: March 2023: This update to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of aminoglycosides in individuals with the MT-RNR1 genotype was precipitated following contact from primary care physicians and pediatricians. These clinicians had asked…

  • CPIC® Guideline for Proton Pump Inhibitors and CYP2C19

    Most recent guideline publication: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020) Updates since publication: No updates on dosing recommendations since publication. Tables provided in the main manuscript of the guideline: Table 1. Assignment of predicted CYP2C19 phenotype based on genotype Table 2. Dosing recommendations for omeprazole, lansoprazole,…

  • CPIC® Guideline for NSAIDs based on CYP2C9 genotype

    Most recent guideline publication: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020) Updates since publication: No updates on dosing recommendations since publication. Tables provided in the main manuscript of the guideline: Table 1. Assignment of likely CYP2C9 phenotypes based on genotypes Table 2. Therapeutic recommendations for celecoxib, flurbiprofen, lornoxicam and…

  • CPIC® Guideline for Efavirenz based on CYP2B6 genotype

    Most recent guideline publication: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-containing Antiretroviral Therapy (April 2019) Updates since publication: No updates on dosing recommendations since publication. Tables and figure provided in the main manuscript of the guideline: Table 1. Assignment of likely CYP2B6 phenotypes based on genotypes Table 2. Efavirenz dosing recommendations based…

  • CPIC® Guideline for Atomoxetine based on CYP2D6 genotype

    Most recent guideline publication: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Atomoxetine (February 2019) Updates since publication: October 2019: CYP2D6 genotype to phenotype translation changes: Up until August 2019, there were a few inconsistencies in the translation of CYP2D6 genotype to phenotype across guidelines (i.e. CPIC and DPWG) and between clinical genetic…

  • CPIC® Guideline for Potent Volatile Anesthetic Agents and Succinylcholine and RYR1 and CACNA1S

    Most recent guideline publication: Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes Updates since publication: December 2023: Subsequent to the publication of the CPIC guideline for RYR1 and malignant hyperthermia (PMID 30499100), the ClinGen variant curation expert panel (VCEP) developed and published…

  • CPIC® Guideline for Tamoxifen based on CYP2D6 genotype

    Most recent guideline publication: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy (January 2018) Updates since publication: October 2019: CYP2D6 genotype to phenotype translation changes: Up until August 2019, there were a few inconsistencies in the translation of CYP2D6 genotype to phenotype across guidelines (i.e. CPIC and DPWG) and between clinical genetic…

  • CPIC® Guideline for Ondansetron and Tropisetron based on CYP2D6 genotype

    Most recent guideline publication: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron (December 2016) Updates since publication: October 2019: CYP2D6 genotype to phenotype translation changes: Up until August 2019, there were a few inconsistencies in the translation of CYP2D6 genotype to phenotype across guidelines (i.e. CPIC and DPWG)…